<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03390244</url>
  </required_header>
  <id_info>
    <org_study_id>FCVB20161101</org_study_id>
    <nct_id>NCT03390244</nct_id>
  </id_info>
  <brief_title>Foldable Capsular Vitreous Body Implantation Study</brief_title>
  <acronym>FCVB</acronym>
  <official_title>Foldable Capsular Vitreous Body Implantation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to evaluate the clinical usefulness of the FCVB in its on-label use,
      but in a different racial type than studies till now (Asians only). The device will be
      inserted in Caucasian patients with permanent loss of functional vision (visual acuity hand
      movements or less), where a permanent use of repeat silicone oil is required to maintain the
      eye pressure.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2, 2017</start_date>
  <completion_date type="Anticipated">May 2, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intra-ocular pressure</measure>
    <time_frame>3 years</time_frame>
    <description>Evaluation of the device as long-term solution for maintenance the intra-ocular pressure, potentially reducing the number of surgeries (silicone oil exchanges) for the patient</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2</enrollment>
  <condition>Vitreoretinal Surgery</condition>
  <arm_group>
    <arm_group_label>FCVB Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects in this study are in the experimental treatment arm and will receive the FCVB implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Foldable Capsular Vitreous Body Implant</intervention_name>
    <description>Vitrectomy augmented with the implantation of the FCVB implant</description>
    <arm_group_label>FCVB Implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged over 18

          -  Axial length between 16 and 28 mm (according the guidelines from the manufacturer)

          -  Loss of functional vision in study eye

          -  Visual acuity of 0.4 or better in fellow eye

          -  Requirement of (repeated) long-term silicone oil tamponade to maintain eye pressure
             and keep the retina attached

        Exclusion Criteria:

          -  Visual acuity beyond 0.4 in non-study eye

          -  Severe general disease that is evaluated to impact live expectancy beyond the duration
             of the study follow-up (3 years)

          -  Retinal detachment under silicone oil fill

          -  Patients with a silica gel allergy or scar diathesis

          -  Patients with serious heart, lung, liver, or kidney dysfunction

          -  Patients with proliferative diabetic retinopathy, endophthalmia, uveitis and other
             uncontrollable eye diseases, or a contralateral eye that had intraocular retinal
             surgery

          -  Patients with history of drug abuse or alcoholism

          -  Patients are had participating in other drug or medical device clinical trials before
             screening for this trial

          -  Pregnancy, preparation for pregnancy during clinical trial, or breast-feeding

          -  Belief by any of the research doctors that a patient's condition would hinder the
             clinical trial, such as a patient prone to mental stress, loss of control of mood, or
             depression
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Stalmans, MD Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Leuven (UZLeuven)</name>
      <address>
        <city>Leuven</city>
        <state>Vl-Brabant</state>
        <zip>B3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2016</study_first_submitted>
  <study_first_submitted_qc>December 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2018</study_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Peter Stalmans</investigator_full_name>
    <investigator_title>Head of Clinic</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

